Digestive Remedies in Brazil
ANVISA is expected to approve the switch of certain ingredients which are globally available over the counter, including omeprazole, which falls under proton pump inhibitors and is still sold as a prescription drug in Brazil. Although it is easy to purchase without a prescription, ANVISA is taking its time to consider the switch as several media outlets in late 2017 reported studies linking the frequent usage of omeprazole with a higher risk of cancer.
Euromonitor International's Digestive Remedies in Brazil report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2014-2018, allowing you to identify the sectors driving growth. Forecasts to 2023 illustrate how the market is set to change.
Product coverage: Diarrhoeal Remedies, IBS Treatments, Indigestion and Heartburn Remedies, Laxatives, Motion Sickness Remedies, Paediatric Digestive Remedies.
Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.
Why buy this report?
* Get a detailed picture of the Digestive Remedies market;
* Pinpoint growth sectors and identify factors driving change;
* Understand the competitive environment, the market’s major players and leading brands;
* Use five-year forecasts to assess how the market is predicted to develop.
Euromonitor International has over 40 years' experience of publishing market research reports, business reference books and online information systems. With offices in London, Chicago, Singapore, Shanghai, Vilnius, Dubai, Cape Town, Santiago, Sydney, Tokyo and Bangalore and a network of over 800 analysts worldwide, Euromonitor International has a unique capability to develop reliable information resources to help drive informed strategic planning.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook